Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, announced today that Tris Vaughan, PhD FRSB has joined its scientific advisory board (SAB).
Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today the appointment of Dr. Stefan Scherer, M.D., Ph.D., to the role of Senior Vice President Clinical Development and Deputy Chief Medical Officer. Dr. Scherer joins Cellectis from Novartis Pharmaceuticals Corporation, where he was the Head of Early Development, Strategy and Innovation for U.S. Oncology.
Cell Medica, a company active in the development, manufacture and marketing of personalised cellular immunotherapeutics for the treatment of cancer, has appointed Chris Nowers as Chief Executive Officer and Executive Director.
Pascal Schmidt appointed CFO as Vienna based biotech firm Marinomedas of August 1 2018.
Morphosys has named Jennifer Herron President of MorphoSys US Inc. to build up sales presence overseas.
The Board of Directors of the company has appointed Dr. Deborah Dunsire as new president and CEO of Lundbeck. Deborah Dunsire will take up her new position on 1 September 2018.
EuropaBio’s Executive Board and General Assembly of Members this week confirmed the appointment of Tjerk de Ruiter as Chairman of the association.
Symcel has announced the appointment of two new board members; Erik Walldén and Stefan Löfås. Both will play a key role in the company’s corporate strategy to grow business in the research market and develop solutions for clinical diagnostics.
Silence Therapeutics plc, a company active in the development of RNA therapeutics, has announced the appointment of Dave Lemus to its Board as Non-Executive Director.
Abivax, a biotechnology company working to develop a functional cure for HIV as well as treatments for inflammatory/autoimmune diseases and cancer, appoints Ian McGowan as Scientific Advisory Board Chair and Juergen Rockstroh as a New Member to the Company’s SAB. The changes have been made to support the transition from a discovery-focused biotechnology company to a biopharmaceutical development company.